Evommune
Latest round
- Series C
Last raised
- Oct 2024
Total raised
- $260M
Investors
- 19
About Evommune
Evommune, Inc.Founded in 2020 and headquartered in Palo Alto, US, Evommune, Inc. specializes in biotech advancements for chronic inflammatory conditions. The company was established under the leadership of CEO Luis Peña, who has a history in the biotechnology sector.Evommune specializes in the development of innovative therapies aimed at treating chronic inflammatory diseases, with a primary focus on conditions such as Chronic Spontaneous Urticaria and Atopic Dermatitis. Their lead product, EVO756, is an MRGPRX2 antagonist currently undergoing Phase 2 clinical trials, targeting the underlying mechanisms of chronic inflammation. Additionally, Evommune is advancing EVO301, an IL-18 targeted fusion protein, also in Phase 2 trials, designed to meet the needs of adult patients suffering from Atopic Dermatitis.Evommune's revenue model is primarily centered around clinical trials and partnerships with the pharmaceutical industry. The company engages in business-to-business transactions, collaborating with healthcare providers and research institutions for therapy development and commercialization. Revenue is generated through strategic partnerships that may involve co-development agreements and licensing deals for its flagship products, such as EVO756 and EVO301. The structure typically includes milestone payments contingent upon regulatory approvals and sales achievements.In October 2024, Evommune, Inc. Evommune plans to introduce new products designed for these conditions and expand into new markets within North America and Europe by 2025.
Who invested in Evommune
19 investors across 4 rounds
See all investors in Evommune
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Evommune
Who invested in Evommune?
Evommune has 19 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Evommune raised?
Evommune has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Evommune last raise money?
Evommune's most recent round on record is a Series C, in Oct 2024.
What does Evommune do?
Evommune is a biotechnology company.
Where is Evommune headquartered?
Evommune is headquartered in Palo Alto, US.
Which VCs invest in companies like Evommune?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Evommune's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Evommune? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.